Scotts Miracle-Gro

Scotts Miracle-Gro Co

Key figures

Period Oct 2024 to Sep 2025ConsolidatedU.S. GAAP

RevenueDisclosed US$3.4B

Operating marginCalculated 10.5%

Net assets to total assetsCalculated Could not be retrieved

Company profile

Ticker SMG / CIK 825542 / Chemicals and pharmaceuticals (SIC 2870) / Fiscal year end 2025-09-30
U.S. GAAP. From the Form 10-K filed with the SEC’s EDGAR.

Tables scroll sideways

Disclosed data

Source: U.S. SEC annual report (Form 10-K) (Oct 2024 to Sep 2025) · filed 2025-11-25

Profitability ★★★☆☆position among all companies 10.5%

Growth (revenue, 4-year average) ★☆☆☆☆position among all companies -8.8%

Capital efficiency Could not be retrieved

Revenue and profit

Performance, financial position and capital allocation

Scotts Miracle-Gro

Recent performance trends

Scotts Miracle-Gro

Cash flow trends

Consolidated indicators (9 items)

Item	4 years ago	3 years ago	2 years ago	Last year	This year
Net sales	US$4.9 billion	US$3.9 billion	US$3.6 billion	US$3.6 billion	US$3.4 billion
Operating income	US$0.7 billion	US$-0.4 billion	US$-0.2 billion	US$0.2 billion	US$0.4 billion
Net income	US$0.5 billion	US$-0.4 billion	US$-0.4 billion	US$-34.90 million	US$0.1 billion
Total assets	US$4.8 billion	US$4.3 billion	US$3.4 billion	US$2.9 billion	US$2.7 billion
Shareholders' equity	US$1.0 billion	Could not be retrieved	Could not be retrieved	Could not be retrieved	Could not be retrieved
Net cash provided by (used in) operating activities	US$0.3 billion	US$-0.1 billion	US$0.5 billion	US$0.7 billion	US$0.4 billion
Net cash provided by (used in) investing activities	US$-0.5 billion	US$-0.3 billion	US$-65.70 million	US$-0.1 billion	US$-0.1 billion
Net cash provided by (used in) financing activities	US$0.5 billion	US$0.3 billion	US$-0.5 billion	US$-0.5 billion	US$-0.3 billion
Cash and cash equivalents	US$0.2 billion	US$86.80 million	US$31.90 million	US$71.60 million	US$36.60 million

Revenue scale in the same industry

Scotts Miracle-Gro

Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed

1 Johnson & JohnsonFY Dec 2025 US$94.2B
2 Procter & GambleFY Jun 2026 US$87.0B
3 ELI Lilly ANDFY Dec 2025 US$65.2B
… 47 companies
51 Fuller H BFY Nov 2025 US$3.5B
52 FMCFY Dec 2025 US$3.5B
53 Scotts Miracle-GroThis companyFY Sep 2025 US$3.4B
54 AvientFY Dec 2025 US$3.3B
55 Biomarin PharmaceuticalFY Dec 2025 US$3.2B
… 1 companies

Sources and methodology

Basic indicators

Item	Value	Consolidated / Non-consolidated	Source
Purchase of property, plant and equipment	US$97.40 million	Consolidated	Disclosed
Cash and cash equivalents	US$36.60 million	Consolidated	Disclosed
Net cash provided by (used in) financing activities	US$-0.3 billion	Consolidated	Disclosed
Net cash provided by (used in) investing activities	US$-0.1 billion	Consolidated	Disclosed
Net cash provided by (used in) operating activities	US$0.4 billion	Consolidated	Disclosed
Depreciation and amortization	US$62.70 million	Consolidated	Disclosed
Dividends paid	US$0.2 billion	Consolidated	Disclosed
Stockholders' equity (including non-controlling interests)	US$-0.4 billion	Consolidated	Disclosed
Net sales	US$3.4 billion	Consolidated	Disclosed
Operating income	US$0.4 billion	Consolidated	Disclosed
Net income	US$0.1 billion	Consolidated	Disclosed
Total assets	US$2.7 billion	Consolidated	Disclosed
Purchase of treasury stock	US$18.40 million	Consolidated	Disclosed
Operating margin	10.5%	Consolidated	Calculated
Net assets to total assets	Cannot be calculated	Not applicable	Not calculated (no stockholders' equity in this year's 10-K)
Net margin	4.3%	Consolidated	Calculated
Return on equity	Cannot be calculated	Not applicable	Not calculated (no stockholders' equity in this year's 10-K)

How to read the figures, and caveats

Terms

Consolidated: the parent company together with the subsidiaries it consolidates
Parent-only: the single company that filed the annual securities report
Calculated: a disclosed figure put through the formula shown
Not disclosed: no such value in the filing (not treated as zero)
Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
Segment: a business division the company uses in its disclosures
Industry median: the middle value among companies in the same industry that disclose the item
★: position when every company is lined up by value (not a judgement of the company)See the formulas
Source: document name, period covered, filing date and where it was obtained
Tables scroll sideways

Key figures

Operating margin 10.5%　Operating income ÷ revenue 　＝ US$0.4 billion ÷ US$3.4 billion
The denominator is revenue under U.S. GAAP (consolidated, U.S. GAAP).
Net margin 4.3%　Net income ÷ revenue 　＝ US$0.1 billion ÷ US$3.4 billion

Cash flow trends

Cash flow (change in cash and cash equivalents) by activity. Operating CF: cash generated by the business. Investing CF: asset purchases, disposals and acquisitions. Financing CF: borrowing, repayments, dividends and share repurchases. Negative: net outflow

Revenue scale in the same industry

Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Data sources and calculation methods

Primary source: the SEC’s EDGAR: Form 10-K of Scotts Miracle-Gro Co (CIK 825542), free to read
Accounting standard: U.S. GAAP / Form: 10-K / Filed: 2025-11-25 / Accession number: 0000825542-25-000022

Amounts: machine transcription of XBRL filed with the SEC’s EDGAR (bulk companyfacts), no manual re-keying. In dollars, not converted to yen (an exchange rate would produce a figure that was never disclosed)
Annual values: full-year figures in the Form 10-K only. Where a restatement gives more than one value for a period, the more recently filed one. Each five-year series from a single element (tag)
Revenue: the company’s elements checked in the order Revenues → RevenueFromContractWithCustomer… → SalesRevenueNet, taking the one with the most recent period. What “revenue” covers may differ between companies
Net income: attributable to the parent’s shareholders. Stockholders’ equity: excluding non-controlling interests (the figure including them on a separate row)
★: position of values calculated from disclosed figures among U.S. companies, on a five-step scale. Separate from Japanese companies because of different accounting standards. Finance (SIC 6000s) in its own set, as revenue is defined differently
Equity-to-asset ratio: no rank (higher or lower is not better or worse). Calculated here as stockholders’ equity ÷ total assets, as U.S. companies do not disclose it (for Japanese companies the field is the company’s disclosed value). Return on equity also calculated here
Industry: first two digits of the SEC’s SIC code. A different classification from the Japanese industry categories (FSA), so shown separately from Japanese companies
Segment breakdown, profit-and-loss flow and cost breakdown: not published (bulk companyfacts holds company-wide figures only). Nothing drawn from guesswork
Share prices: not used. Employee counts: only where the 10-K XBRL carries them as a number